Press Releases

GENEVA, Switzerland, May 24, 2024 (GLOBE NEWSWIRE) -- Etrion Corporation (“Etrion” or the “Company”, and, together with its subsidiaries, the “Group”) released today its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three months ended March 31, 2024.

Q1-24 HIGHLIGHTS

• Etrion closed the first quarter of 2024 with an unrestricted cash balance of US$6.3 million and a positive... (continue reading...)

Vancouver, British Columbia--(Newsfile Corp. - May 24, 2024) - Q2 Metals Corp. (TSXV: QTWO) (OTCQB: QUEXF) (FSE: 458) ("Q2" or the "Company") announces that subject to acceptance by the TSX Venture Exchange (the "TSXV"), the Company intends to amend the exercise price of an aggregate of 12,908,333 outstanding common share purchase warrants of the Company that were issued as part of the Company's private placement that closed on February 23, 2023 (the "Warrants").

The... (continue reading...)

Improvement in Gross Margin and Adjusted EBITDA Continues in 2024

TORONTO, ON / ACCESSWIRE / May 24, 2024 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data driven software and solutions, announced its financial results today for the first quarter ended March 31, 2024.

Interest in the EQ suite of products increased significantly during the first quarter of 2024. Revenue of $1.6 million was relatively in line with the previous year, however,... (continue reading...)

Winnipeg, Manitoba--(Newsfile Corp. - May 24, 2024) - Snow Lake Resources Ltd., d/b/a Snow Lake Energy (NASDAQ: LITM) ("Snow Lake" or the "Company") announces that on May 24, 2024, it received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common shares ("Shares") has been below US $1.00 per share for 30... (continue reading...)

Z�RICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ: NLSP)(NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that on May 22, 2024, the Company received an additional staff determination letter (the "Letter") from the staff (the "Staff") of the Listing... (continue reading...)